Mayo Clinic Laboratories > BioPharma Diagnostics > Testing

testing

SPECIALTY TESTING TO EXPEDITE SOLUTIONS

With BioPharma Diagnostics, you have access to Mayo Clinic Laboratories' expansive clinical test menu, including more than 4,400 tests. In addition to offering the world’s most sophisticated specialty test menu, we provide access to research-grade tests, pathology services, and sponsored testing programs, availing unparalleled testing expertise to our biopharma partners.

To learn more about our testing, view our biopharma-specific test catalog and full test catalog.

26 million

26 million tests and pathology services performed in 2022

14

14 areas of subspecialty testing

77

77 new tests launched in 2022

Test menu

Gastroenterology Gastroenterology
Gastroenterology

With more than 330 tests in our gastroenterology test catalog, our GI testing plays a key role in establishing Mayo Clinic as the nation's leading gastroenterology and GI surgery hospital. From routine serological testing to specialized fecal testing to advanced biomarker evaluations, our menu offers an array of methodologies to test and guide treatment for a range of GI disorders.

Hematology Hematology
Hematology

We offer a robust library of expert-backed hematology evaluations designed to improve outcomes, increase efficiency, and decrease costs. Our hematology testing laboratories are led by board-certified hematologists and hematopathologists who focus on molecular diagnostics and prognostics of hematologic disorders.

Infectious diseases Infectious diseases
Infectious diseases

Performing more than three million tests annually, our infectious disease and clinical microbiology laboratories have developed and implemented innovative in vitro and culture techniques, immunoassays, antimicrobial susceptibility testing, and molecular models for rapid detection, identification, and characterization of microbes. Our comprehensive testing menu offers a broad selection of tests for rapid identification and in-depth characterization of the causative agents of infectious disease.

Neurology Neurology
Neurology

BioPharma Diagnostics offers access to some of the world’s most esoteric and advanced neurologic testing. Our assays span the neurologic disease spectrum and include genetic and biochemical biomarker evaluations for Alzheimer’s disease; extensive offerings to evaluate for autoimmune neurologic disorders; next-generation sequencing to identify neurogenetic illness; and other assays.

Oncology Oncology
Oncology

Our extensive oncology test menu features a broad range of biomarker testing to assist with determining diagnosis and treatment effectivity across the full spectrum of solid tumor malignancies. From single gene and tumor-specific genetic panels to MayoComplete next-generation sequencing to immune profiling, our oncology assays are developed and validated in collaboration with Mayo Clinic oncologists, pathologists, geneticists, and laboratorians.

Rare diseases Rare diseases
Rare diseases

Affecting 25 million to 30 million Americans and manifesting in as many as 7,000 different forms, the cumulative impact of rare diseases is huge.  Our genetic testing was developed by geneticists, genetic counselors, laboratory scientists, and bioinformaticians and employs a variety of genetic sequencing techniques to identify and confirm rare disease.

Renal Renal
Renal

Our renal diagnostics are backed by a multidisciplinary approach and an award-winning team of Mayo Clinic nephrology experts, pathologists, and laboratory scientists who work at the intersection of research and patient care.

Therapeutics Therapeutics
Therapeutics

Developed through evidence-driven clinical innovation and designed to deliver clarity on drug and alcohol use, our testing delivers results that advance understanding and improve outcomes.

Expert-driven innovation

Our dedicated CAP-affiliated laboratory directors are board-certified physicians and clinical laboratory scientists who engage in clinical practice as well as research. Bringing clinical experience to the test development arena enables evidence-based innovation rooted in patient outcomes. A partnership with BioPharma Diagnostics provides access to a vast testing library as well as a wealth of patient-centric expertise to optimize clinical trial and drug development.

“Laboratory medicine creates amazing value for any healthcare organization because it's creating data and that data is very valuable. It can drive practice, it can drive cost, it can drive cost deflection, and it can drive insights.”

William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories

News and updates

The latest

Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

Learn more
Expanded colorectal cancer panel tests more genes

Mayo Clinic Laboratories has developed a new colorectal cancer test, the MayoComplete Colorectal Cancer Panel (Mayo ID: MCCRC), in response to the latest recommendations for testing and treatment from the American Society of Clinical Oncology.

GIST panel detects more gene mutations

The MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor evaluates for somatic mutations in solid tumor samples and determines microsatellite instability to confirm a diagnosis of GIST.

Next-generation sequencing lung cancer panel identifies more genetic abnormalities

Mayo Clinic Laboratories’ new MayoComplete Lung Cancer Panel (Mayo ID: MCLNG) provides more information than single-gene assays and faster results than a comprehensive solid tumor panel that covers hundreds of genes.

Study identifies critical link between inflammation and liver regeneration

Mayo Clinic researchers and collaborators have discovered a critical role that inflammation plays in liver regeneration after liver resection. While effective regeneration requires some inflammation, too much of it causes regeneration failure. They also discovered that patients experiencing dysfunctional liver regeneration had a significantly dysregulated gene known as DUSP4 – a finding that could help support targeted therapeutic strategies administered before or after surgical resection to prevent liver failure.

Artificial intelligence paves way for earlier detection of gastrointestinal cancers

Mayo Clinic researchers are now using artificial intelligence (AI) systems to help increase polyp detection during colonoscopies and identify colorectal cancer at an early stage. Like facial recognition software that recognizes faces, this AI tool is being trained to recognize polyps. It works alongside the physician during a colonoscopy, scanning the video feed and drawing boxes around polyps that may otherwise have been overlooked due to their subtleness.

Noninvasive DNA testing via liquid biopsy

The MayoComplete Liquid Biopsy Panel offers a noninvasive alternative to traditional cell-based biopsies. This allow for faster turnaround time and the ability to perform molecular DNA testing in cancer patients where tumor tissue isn’t available.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.